Results 321 to 330 of about 9,385,080 (408)

Effects of aquatic high-intensity interval training on aerobic capacity in adults with rheumatic and musculoskeletal diseases: the AquaHigh randomised controlled trial. [PDF]

BMJ Open
Bunæs-Næss H, Heywood SE, Kvæl LAH, Heiberg KE, Nilsson BB.   +4 more
europepmc   +1 more source

Burden of musculoskeletal diseases increasing [PDF]

Nature Reviews Rheumatology, 2019
openaire   +3 more sources

Rheumatic and Musculoskeletal Diseases and Risk of Dementia: A Nested Case-Control Study. [PDF]

ACR Open Rheumatol
Kiadaliri A, Dell'Isola A, Turkiewicz A, Englund M.   +3 more
europepmc   +1 more source

Machine Learning–Driven Screening of High‐Activity Antitumor Nanozymes Using an Ensemble Enzymatic Oracle System

Cancer Nexus, EarlyView.
ABSTRACT Nanozymes, by mimicking the catalytic sites of natural enzymes, have emerged as effective substitutes for traditional natural enzymes. However, the relationship between the physicochemical properties and activity of nanozymes is complex and nonlinear.
Guanmeng Zhang, Mutian Yang, Jie Zang, Xiaoli Li, Qinqiu Zhong, Yuxiang Hu, Yumeng Xie, Ludan Zhang, Yuping Qian, Jinna Ren, Yang Peng, Haitao Chen, Jiandong Gao, Ji Wu, Yuguang Wang   +14 more
wiley   +1 more source

Osteoarthritis of the Knee as One of the Major Musculoskeletal Diseases Responsible for Locomotive Syndrome: The Role of Synovitis in Pain

, 2014
Muneaki Ishijima, Haruka Kaneko, Mitsuaki Kubota, Lizu Liu, R. Sadatsuki, S. Hada, Mayuko Kinoshita, ANWARJAN YUSUP, I. Futami, Yuko Sakamoto, Yukio Shimura, Kiyohito Naïto, Taiji Watari, Yoshitomo Saita, Yuji Takazawa, Sung‐Gon Kim, Hiroshi Ikeda, Isao Nagaoka, Eri Arikawa‐Hirasawa, Hisashi Kurosawa, Kazuo Kaneko   +20 more
openalex   +2 more sources

Dose Determinations at Drug Approval Reviews: FDA‐Approved Drugs in Past 5 Years

Clinical Pharmacology &Therapeutics, EarlyView.
Drug dose appropriateness is one of the most discussed issues in regulatory reviews. We analyzed dose determinations during Food and Drug Administration (FDA) drug reviews to determine whether there were changes between the proposed and approved doses of new molecular entities (NMEs), including cases where postmarketing dose‐finding studies were ...
Sachiko Mita, Shunsuke Ono
wiley   +1 more source

The Role of Artificial Intelligence in the Primary Prevention of Common Musculoskeletal Diseases. [PDF]

Cureus
Yilmaz Muluk S, Olcucu N.
europepmc   +1 more source

INFLUENCE OF WORKING CONDITIONS ON THE OCCURRENCE AND PREVALENCE OF DISEASES MUSCULOSKELETAL SYSTEM OF THE WORKERS OF LLC "TOLYATTI TRANSFORMER"

, 2014
E. V. Semina, O. A. Rozenzvet
openalex   +2 more sources

First‐in‐Human Single and Multiple Ascending Dose Studies of Balinatunfib, a Small Molecule Inhibitor of TNFR1 Signaling in Healthy Participants

Clinical Pharmacology &Therapeutics, EarlyView.
Oral small molecule inhibitors of tumor necrosis factor alpha (TNFα) are emerging as attractive therapeutic agents for the treatment of various autoimmune diseases. Balinatunfib (SAR441566), a novel oral inhibitor of tumor necrosis factor receptor 1 (TNFR1) signaling, changes the configuration of the soluble TNFα (sTNFα) trimer and prevents its ...
Nassr Nassr, Faiza Rharbaoui, Dietmar Weitz, Johann Gassenhuber, Markus Rehberg, Markus Kohlmann, Fabienne Schumacher, Amel Lahmar, Andreas Kovar, Laurent Perrin, Frank‐Dietrich Wagner, Maria Wiekowski, Mai Anh Nguyen   +12 more
wiley   +1 more source

Preparing the soil: Adjusting the metabolic health of patients with chronic wounds and musculoskeletal diseases. [PDF]

Int Wound J
da Fonseca LF, Santos GS, Azzini G, Mosaner T, Jorge DMF, de Macedo AP, Huber SC, Sobreiro P, Dallo I, Jeyaraman M, Everts PA, Navani A, Lana JF.   +12 more
europepmc   +1 more source